ClinicalTrials.gg
CompletedNCT01456676Updated Dec 9, 2020

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

A Phase 1 interventional study of Nilotinib + LDE225 in Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 7 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
55th of 66
11 · median 55
Started
2012
with 5 others
Phase 1
6 of 66
none open now
Registered
31st of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 55th largest by enrollment, is one of 6 that started in 2012, is one of 6 in phase 1, and was the 31st registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The purpose of this study is to determine the feasibility of administering the combination of nilotinib and LDE225 to patients with chronic or accelerated phase of chronic myeloid leukemia and to establish the maximum tolerated dose (MTD) and/or recommended Phase II dose level (RP2D) of LDE225 in combination with nilotinib.

03

Conditions studied

  • Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Keywords

  • LDE225
  • nilotinib
  • Chronic myeloid leukemia
  • CML
  • Philadelphia positive
  • Ph+
  • resistant
  • Resistant Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Philadelphia chromosome positive (Ph+) CML in chronic phase (CP) or accelerated phase (AP)with resistance to at least one prior BCR-ABL targeting TKI
  2. Documented chronic phase CML
  3. Adequate end organ function
  4. Female patients of must have a negative serum pregnancy test and must be using highly effective methods of . Male patients with female partners of child-bearing potential must use condoms.

Exclusion criteria

Exclusion Criteria:

  1. Impaired cardiac function
  2. Severe and/or uncontrolled concurrent disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
  3. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
  4. Patients actively receiving therapy with strong inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to entering the study
  5. Patients who are currently receiving treatment with any medications that have the potential to prolong the and the treatment cannot be either safely discontinued or switched to a different medication prior to starting study drug.
  6. Previously documented BCR-ABL Y253H, E255K/V, T315I or F359C/V mutation

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Nilotinib + LDE225

    The planned dose of nilotinib 400 mg b.i.d (twice a day) was selected for the combination as this is the dose approved for the treatment of the patient population that will be included in the present study. The starting dose for LDE225 chosen for the current study is 400 mg once daily(q.d.). The maximum dose of LDE225 that will be tested in combination with nilotinib is 800 mg once dail.y

    Drug: Nilotinib + LDE225

Interventions

  • DrugNilotinib + LDE225

    Drug pages: Nilotinib · Sonidegib

    Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.

06

What researchers measure

Primary outcomes

  1. Incidence rate and category of dose limiting toxicities (DLTs) during the first two cycles of therapy

    Determination of the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of nilotinib in combination with LDE225

    Time frame: 56 days (2 treatment cycles at 28 days each)

Secondary outcomes

  1. No of participants with Adverse drug reactions and serious adverse drug reactions, changes in hematology and blood chemistry values, assessments of physical examinations, vital signs and electrocardiograms

    Assessment of the safety and tolerability profile of nilotinib in combination with LDE225

    Time frame: 336 days (12 treatment cycles)

  2. Plasma concentration and basic pharmacokinetics (PK) parameters (as Cmax, Tmax, AUC)

    Assessment of the PK characteristics of nilotinib administered in combination with LDE225

    Time frame: 50 days

  3. Major molecular response (MMR) rates at 3, 6 and 12 months

    Determination of the kinetics of major molecular response

    Time frame: 336 days (12 treatment cycles)

  4. Complete molecular response (CMR) rates at 3, 6 and 12 months

    Determination of the kinetics of complete molecular response

    Time frame: 336 days (12 treatment cycles)

  5. Major cytogenic response (MCyR) rates by 3, 6 and 12 months

    Determination of major cytogenetic response rates

    Time frame: 336 days (12 treatment cycles)

  6. Complete cytogenic response (CCyR) rates by 3, 6 and 12 months

    Determination of complete cytogenetic response rates

    Time frame: 336 days (12 treatment cycles)

07

Study locations

7 sites
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Pamplona, Navarra 31008, Spain
  • Novartis Investigative Site
    Madrid, 28006, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2011
First posted
Oct 21, 2011
Start
Jan 2012
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Last update
Dec 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01456676
Responsible party
Sponsor
First posted
Oct 21, 2011
Start date
Jan 2012
Primary completion
Feb 2014
Completion
Feb 2014
Last update
Dec 9, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nilotinib · Sonidegib

Start the discussion